Pharmacologic Background and Clinical Issue of Anti-influenza Drugs

Overview

Journal Fukushima J Med Sci

Specialty General Medicine

Date 2024 Dec 18

PMID 39694499

Authors

Masatoki Sato

Affiliations

Soon will be listed here.

Abstract

Since 2000, rapid antigen detection kits and anti-influenza drugs have been used for the early diagnosis and treatment of influenza in Japan, respectively.　The main drugs available in clinical practice are the neuraminidase inhibitors oseltamivir, zanamivir, laninamivir, and peramivir, as well as the cap-dependent endonuclease inhibitor baloxavir marboxil.　Antiviral therapy with neuraminidase inhibitors has been practiced for many years, especially in Japan; it can shorten the febrile period and reduce complications.　Despite having similar structures, the pharmacologic background of neuraminidase inhibitors differs significantly, as reflected in their varying clinical efficacy.　Due to its inhibitory mechanism, baloxavir marboxil can rapidly reduce the viral load than neuraminidase inhibitors.　However, the duration of symptoms was similar after the administration of baloxavir marboxil and oseltamivir, and variants with reduced drug susceptibility have been detected in 20%-30% of pediatric patients treated with baloxavir marboxil.　Clinical trials of several novel anti-influenza drugs are currently underway.　When these drugs are first marketed, the characteristics of the influenza virus and the pharmacologic background of the drugs must be clarified before their administration to patients in clinical practice.

References

Hirotsu N, Sakaguchi H, Sato C, Ishibashi T, Baba K, Omoto S . Baloxavir Marboxil in Japanese Pediatric Patients With Influenza: Safety and Clinical and Virologic Outcomes. Clin Infect Dis. 2019; 71(4):971-981. PMC: 7428393. DOI: 10.1093/cid/ciz908. View

Whitley R, Hayden F, Reisinger K, Young N, Dutkowski R, Ipe D . Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J. 2001; 20(2):127-33. DOI: 10.1097/00006454-200102000-00002. View

Heldt F, Frensing T, Reichl U . Modeling the intracellular dynamics of influenza virus replication to understand the control of viral RNA synthesis. J Virol. 2012; 86(15):7806-17. PMC: 3421648. DOI: 10.1128/JVI.00080-12. View

Oo C, Hill G, Dorr A, Liu B, Boellner S, Ward P . Pharmacokinetics of anti-influenza prodrug oseltamivir in children aged 1-5 years. Eur J Clin Pharmacol. 2003; 59(5-6):411-5. DOI: 10.1007/s00228-003-0639-6. View

Watanabe A, Chang S, Kim M, Chu D, Ohashi Y . Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: A double-blind, randomized, noninferiority clinical trial. Clin Infect Dis. 2010; 51(10):1167-75. DOI: 10.1086/656802. View

Kohno S, Kida H, Mizuguchi M, Shimada J . Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection. Antimicrob Agents Chemother. 2010; 54(11):4568-74. PMC: 2976170. DOI: 10.1128/AAC.00474-10. View

Lew W, Chen X, Kim C . Discovery and development of GS 4104 (oseltamivir): an orally active influenza neuraminidase inhibitor. Curr Med Chem. 2000; 7(6):663-72. DOI: 10.2174/0929867003374886. View

Koyama K, Takahashi M, Oitate M, Nakai N, Takakusa H, Miura S . CS-8958, a prodrug of the novel neuraminidase inhibitor R-125489, demonstrates a favorable long-retention profile in the mouse respiratory tract. Antimicrob Agents Chemother. 2009; 53(11):4845-51. PMC: 2772300. DOI: 10.1128/AAC.00731-09. View

Yokoyama T, Sakaguchi H, Ishibashi T, Shishido T, Piedra P, Sato C . Baloxavir Marboxil 2% Granules in Japanese Children With Influenza: An Open-label Phase 3 Study. Pediatr Infect Dis J. 2020; 39(8):706-712. PMC: 7360099. DOI: 10.1097/INF.0000000000002748. View

10.

Watanabe A . A randomized double-blind controlled study of laninamivir compared with oseltamivir for the treatment of influenza in patients with chronic respiratory diseases. J Infect Chemother. 2012; 19(1):89-97. DOI: 10.1007/s10156-012-0460-1. View

11.

Matsuo Y, Ishibashi T, Hollister A, Wajima T . Population pharmacokinetics of peramivir in healthy volunteers and influenza patients. Antimicrob Agents Chemother. 2015; 59(11):6755-62. PMC: 4604349. DOI: 10.1128/AAC.00799-15. View

12.

Hause B, Collin E, Liu R, Huang B, Sheng Z, Lu W . Characterization of a novel influenza virus in cattle and Swine: proposal for a new genus in the Orthomyxoviridae family. mBio. 2014; 5(2):e00031-14. PMC: 3958797. DOI: 10.1128/mBio.00031-14. View

13.

Sugaya N, Mitamura K, Yamazaki M, Tamura D, Ichikawa M, Kimura K . Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children. Clin Infect Dis. 2006; 44(2):197-202. DOI: 10.1086/509925. View

14.

Laver W, Bischofberger N, Webster R . Disarming flu viruses. Sci Am. 1999; 280(1):78-87. DOI: 10.1038/scientificamerican0199-78. View

15.

Meindl P, Bodo G, Palese P, Schulman J, Tuppy H . Inhibition of neuraminidase activity by derivatives of 2-deoxy-2,3-dehydro-N-acetylneuraminic acid. Virology. 1974; 58(2):457-63. DOI: 10.1016/0042-6822(74)90080-4. View

16.

Sato M, Takashita E, Katayose M, Nemoto K, Sakai N, Fujisaki S . Detection of Variants With Reduced Baloxavir Marboxil and Oseltamivir Susceptibility in Children With Influenza A During the 2019-2020 Influenza Season. J Infect Dis. 2021; 224(10):1735-1741. DOI: 10.1093/infdis/jiab196. View

17.

Wattanagoon Y, Stepniewska K, Lindegardh N, Pukrittayakamee S, Silachamroon U, Piyaphanee W . Pharmacokinetics of high-dose oseltamivir in healthy volunteers. Antimicrob Agents Chemother. 2008; 53(3):945-52. PMC: 2650521. DOI: 10.1128/AAC.00588-08. View

18.

Sato M, Hosoya M, Kato K, Suzuki H . Viral shedding in children with influenza virus infections treated with neuraminidase inhibitors. Pediatr Infect Dis J. 2005; 24(10):931-2. DOI: 10.1097/01.inf.0000180976.81055.ce. View

19.

Katsumi Y, Otabe O, Matsui F, Kidowaki S, Mibayashi A, Tsuma Y . Effect of a single inhalation of laninamivir octanoate in children with influenza. Pediatrics. 2012; 129(6):e1431-6. DOI: 10.1542/peds.2011-2054. View

20.

Kakuya F, Okubo H, Fujiyasu H, Kurisawa M, Kinebuchi T . Clinical effectiveness of baloxavir marboxil against influenza in three seasons. Pediatr Int. 2022; 64(1):e15169. DOI: 10.1111/ped.15169. View